Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975608 | 0.91 | TRPM8 (0.46) | MAPTTRPM8SIRT2SIRT1RARA | |
| SCHEMBL8238620 | 0.89 | RARA (0.54) | MAPTTRPM8SIRT2SIRT1RARA | |
| SCHEMBL8242411 | 0.86 | MAPT (0.51) | MAPTRARARARBRARGRAB9A | |
| SCHEMBL7217168 | 0.82 | KDM4E (0.66) | MAPTTRPM8RAB9AKDM4ENPC1 | |
| SCHEMBL9975603 | 0.77 | SMN1; SMN2 (0.47) | MAPTTRPM8RARARARBRARG | |
| SCHEMBL8239693 | 0.77 | RARA (0.53) | MAPTTRPM8RARARARBRARG | |
| SCHEMBL8345149 | 0.76 | RAB9A (0.69) | MAPTTRPM8RAB9ANPC1MEN1 | |
| SCHEMBL8239864 | 0.76 | RARA (0.52) | MAPTTRPM8RARARARBRARG | |
| SCHEMBL8239699 | 0.76 | MAPT (0.46) | MAPTRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL9975604 | 0.75 | RARA (0.51) | MAPTTRPM8RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394798-B2 | Compositions and methods for inducing neuronal differentiation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120157457-A1 | COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157457-A1 | COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2012-06-21 | — | — | US | disclosed |
| US-8105581-B2 | Compositions and methods for inducing neuronal differentiation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100166710-A1 | Compositions and Methods for Inducing Neuronal Differentiation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166710-A1 | Compositions and Methods for Inducing Neuronal Differentiation | CHAT, DCX, GAP43 | MAPT 355/4885TRPM8 3626/4885SIRT2 2921/4885 |
| US-20120157457-A1 | COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION | CHAT, DCX, GAP43 | MAPT 355/4885TRPM8 3626/4885SIRT2 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.